PD-1: Its Discovery, Involvement in Cancer Immunotherapy, and Beyond

Yasumasa Ishida1

  • 1Division of Biological Science, Nara Institute of Science and Technology, 8916-5 Takayama-cho, Ikoma-shi, Nara 630-0192, Japan.

Cells
|June 5, 2020
PubMed

Insights

The programmed death-1 (PD-1) molecule, crucial in immune research, has a long history. Further research is needed to fully understand PD-1's role in the immune system's self-nonself discrimination.

Area of Science:

  • Immunology
  • Molecular Biology
  • Biochemistry

Background:

  • The programmed death-1 (PD-1) molecule was first isolated in the early 1990s.
  • The significance of PD-1 in biological research was recognized with the 2018 Nobel Prize in Physiology or Medicine.
  • Despite advancements, the full implications of PD-1 research are still being explored.

Purpose of the Study:

  • To review the historical journey of programmed death-1 (PD-1) research.
  • To discuss the ongoing research and future directions in the field of PD-1.
  • To highlight the potential roles of PD-1 in immune system's self-nonself discrimination.

Main Methods:

  • Literature review of programmed death-1 (PD-1) research.
  • Analysis of PD-1's function in immunological self-nonself discrimination.
  • Discussion of historical context and future perspectives in PD-1 research.

Main Results:

  • The isolation of the PD-1 molecule in the early 1990s marked a significant milestone.
  • The 2018 Nobel Prize underscored the importance of PD-1 research.
  • PD-1 plays a critical role in the immune system's ability to distinguish self from non-self.

Conclusions:

  • The journey of programmed death-1 (PD-1) research is extensive, with significant milestones achieved.
  • Further investigation is essential to fully elucidate the complex functions of PD-1.
  • Understanding PD-1's role in self-nonself discrimination is crucial for advancing immunology and medicine.

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.6K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
868
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K